Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

INTRODUCTION: Abiraterone acetate plus prednisone (AA+P) has shown to significantly improve survival. COSMiC, a Canadian Observational Study in Metastatic Cancer of the Prostate, set out to prospectively amass real-world data on metastatic castration-resistant prostate cancer (mCRPC) patients manage...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Can Urol Assoc J
Main Authors: Gotto, Geoffrey, Drachenberg, Darrel E., Chin, Joseph, Casey, Richard, Fradet, Vincent, Sabbagh, Robert, Shayegan, Bobby, Rendon, Ricardo A., Danielson, Brita, Camacho, Fernandes, Zardan, Anousheh, Plante, Richard, Hew, Huong, Chan, Katherine, Feifer, Andrew
פורמט: Artigo
שפה:Inglês
יצא לאור: Canadian Medical Association 2020
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7704085/
https://ncbi.nlm.nih.gov/pubmed/32569568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.6388
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים